$119.82
Live
Insights on Zimmer Biomet Holdings, Inc.
Revenue is up for the last 2 quarters, 1.75B → 1.94B (in $), with an average increase of 9.6% per quarter
Netprofit is up for the last 2 quarters, 162.7M → 419.2M (in $), with an average increase of 61.2% per quarter
In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 55.6%
In the last 3 years, Boston Scientific Corp. has given 70.6% return, outperforming this stock by 102.4%
0.84%
Downside
Day's Volatility :1.89%
Upside
1.05%
15.2%
Downside
52 Weeks Volatility :31.39%
Upside
19.1%
Period | Zimmer Biomet Holdings, Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -0.65% | 1.7% | 3.6% |
6 Months | 16.91% | 11.3% | 21.1% |
1 Year | -12.86% | 5.4% | 24.6% |
3 Years | -31.04% | 13.9% | 21.3% |
Market Capitalization | 25.1B |
Book Value | $60.7 |
Dividend Share | 0.96 |
Dividend Yield | 0.79% |
Earnings Per Share (EPS) | 4.89 |
PE Ratio | 24.97 |
PEG Ratio | 4.69 |
Wall Street Target Price | 137.17 |
Profit Margin | 13.85% |
Operating Margin TTM | 23.7% |
Return On Assets TTM | 4.4% |
Return On Equity TTM | 8.36% |
Revenue TTM | 7.4B |
Revenue Per Share TTM | 35.43 |
Quarterly Revenue Growth YOY | 6.3% |
Gross Profit TTM | 4.9B |
EBITDA | 2.4B |
Diluted Eps TTM | 4.89 |
Quarterly Earnings Growth YOY | -0.16 |
EPS Estimate Current Year | 8.06 |
EPS Estimate Next Year | 8.68 |
EPS Estimate Current Quarter | 2.15 |
EPS Estimate Next Quarter | 1.91 |
What analysts predicted
Upside of 14.48%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.9B | ↑ 1.39% |
Net Income | -379.2M | ↓ 120.61% |
Net Profit Margin | -4.78% | ↓ 28.29% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.0B | ↑ 0.62% |
Net Income | 1.1B | ↓ 398.42% |
Net Profit Margin | 14.18% | ↑ 18.96% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.0B | ↓ 12.0% |
Net Income | -137.4M | ↓ 112.14% |
Net Profit Margin | -1.96% | ↓ 16.14% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 6.8B | ↓ 2.81% |
Net Income | 401.6M | ↓ 392.29% |
Net Profit Margin | 5.88% | ↑ 7.84% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.9B | ↑ 1.65% |
Net Income | 231.4M | ↓ 42.38% |
Net Profit Margin | 3.33% | ↓ 2.55% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 7.4B | ↑ 6.55% |
Net Income | 1.0B | ↑ 342.52% |
Net Profit Margin | 13.85% | ↑ 10.52% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.7B | ↓ 6.29% |
Net Income | 194.0M | ↑ 26.22% |
Net Profit Margin | 11.62% | ↑ 2.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.8B | ↑ 9.3% |
Net Income | -130.2M | ↓ 167.11% |
Net Profit Margin | -7.13% | ↓ 18.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8B | ↑ 0.32% |
Net Income | 232.5M | ↓ 278.57% |
Net Profit Margin | 12.7% | ↑ 19.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 2.11% |
Net Income | 209.6M | ↓ 9.85% |
Net Profit Margin | 11.21% | ↓ 1.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8B | ↓ 6.2% |
Net Income | 162.7M | ↓ 22.38% |
Net Profit Margin | 9.28% | ↓ 1.93% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 10.64% |
Net Income | 419.2M | ↑ 157.65% |
Net Profit Margin | 21.61% | ↑ 12.33% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 24.1B | ↓ 8.58% |
Total Liabilities | 12.9B | ↓ 12.19% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 24.6B | ↑ 2.12% |
Total Liabilities | 12.2B | ↓ 4.71% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 24.4B | ↓ 0.9% |
Total Liabilities | 12.2B | ↓ 0.23% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 23.5B | ↓ 3.94% |
Total Liabilities | 10.8B | ↓ 11.69% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 21.1B | ↓ 10.19% |
Total Liabilities | 9.0B | ↓ 16.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 21.5B | ↑ 2.05% |
Total Liabilities | 9.0B | ↓ 0.34% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 21.3B | ↓ 0.56% |
Total Liabilities | 9.1B | ↓ 2.64% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 21.1B | ↓ 1.25% |
Total Liabilities | 9.0B | ↓ 0.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.2B | ↑ 0.84% |
Total Liabilities | 9.1B | ↑ 0.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.3B | ↑ 0.24% |
Total Liabilities | 8.9B | ↓ 1.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.2B | ↓ 0.36% |
Total Liabilities | 8.7B | ↓ 2.43% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.5B | ↑ 1.32% |
Total Liabilities | 9.0B | ↑ 3.56% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↑ 10.43% |
Investing Cash Flow | -416.6M | ↓ 18.44% |
Financing Cash Flow | -1.3B | ↑ 7.58% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↓ 9.25% |
Investing Cash Flow | -729.3M | ↑ 75.06% |
Financing Cash Flow | -779.9M | ↓ 40.11% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↓ 24.04% |
Investing Cash Flow | -613.8M | ↓ 15.84% |
Financing Cash Flow | -421.8M | ↓ 45.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↑ 24.47% |
Investing Cash Flow | -503.6M | ↓ 17.95% |
Financing Cash Flow | -1.3B | ↑ 209.63% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↓ 14.31% |
Investing Cash Flow | -529.2M | ↑ 5.08% |
Financing Cash Flow | -843.8M | ↓ 35.39% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 450.8M | ↑ 27.89% |
Investing Cash Flow | -85.2M | ↓ 64.97% |
Financing Cash Flow | -193.9M | ↑ 32.81% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 244.2M | ↓ 45.83% |
Investing Cash Flow | -529.2M | ↑ 521.13% |
Financing Cash Flow | -313.4M | ↑ 61.63% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 307.7M | ↑ 26.0% |
Investing Cash Flow | -149.4M | ↓ 71.77% |
Financing Cash Flow | -206.7M | ↓ 34.05% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 347.9M | ↑ 13.06% |
Investing Cash Flow | -392.5M | ↑ 162.72% |
Financing Cash Flow | -109.4M | ↓ 47.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 337.6M | ↓ 2.96% |
Investing Cash Flow | -558.1M | ↑ 42.19% |
Financing Cash Flow | -196.0M | ↑ 79.16% |
Sell
Neutral
Buy
Zimmer Biomet Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Zimmer Biomet Holdings, Inc. | -5.27% | 16.91% | -12.86% | -31.04% | -2.85% |
Stryker Corporation | -4.04% | 30.03% | 12.47% | 26.98% | 79.97% |
Dexcom, Inc. | -1.59% | 63.45% | 11.22% | 31.69% | 366.88% |
Boston Scientific Corp. | 8.35% | 45.85% | 42.65% | 72.49% | 97.43% |
Abbott Laboratories | -2.84% | 14.24% | -2.8% | -12.8% | 36.85% |
Medtronic Plc | -3.44% | 12.58% | -10.38% | -38.23% | -7.46% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Zimmer Biomet Holdings, Inc. | 24.97 | 24.97 | 4.69 | 8.06 | 0.08 | 0.04 | 0.01 | 60.7 |
Stryker Corporation | 40.64 | 40.64 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Dexcom, Inc. | 102.89 | 102.89 | 2.53 | 1.76 | 0.26 | 0.06 | NA | 5.37 |
Boston Scientific Corp. | 64.48 | 64.48 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Abbott Laboratories | 33.52 | 33.52 | 5.99 | 4.31 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.81 | 25.81 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Zimmer Biomet Holdings, Inc. | Hold | $25.1B | -2.85% | 24.97 | 13.85% |
Stryker Corporation | Buy | $127.4B | 79.97% | 40.64 | 15.44% |
Dexcom, Inc. | Buy | $54.6B | 366.88% | 102.89 | 14.95% |
Boston Scientific Corp. | Buy | $101.4B | 97.43% | 64.48 | 11.18% |
Abbott Laboratories | Buy | $186.7B | 36.85% | 33.52 | 13.96% |
Medtronic Plc | Buy | $107.9B | -7.46% | 25.81 | 13.0% |
Vanguard Group Inc
BlackRock Inc
Dodge & Cox
T. Rowe Price Associates, Inc.
State Street Corporation
Amvescap Plc.
In the quarter ending March,2024. Zimmer Biomet Holdings, Inc. has declared dividend of $0.24
Read Morezimmer biomet is the world’s most trusted brand for personalized bone and joint healthcare solutions. we help people discover and achieve exceptional outcomes. as a leading innovator in musculoskeletal healthcare, we offer a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. every day, we focus on improving musculoskeletal healthcare. it’s all we do. it’s all we’ve ever done. for nearly 90 years, zimmer biomet has helped people progress beyond their pain and limitations. because it’s not just what we make, it’s what we make possible. zimmer biomet serves healthcare professionals and their patients globally. our worldwide headquarters is in warsaw, indiana, usa.
Organization | Zimmer Biomet Holdings, Inc. |
Employees | 18000 |
CEO | Mr. Ivan Tornos |
Industry | Health Technology |
Spdr Portfolio Large Cap Etf
$119.82
-1.11%
Canadian National Railway Company
$119.82
-1.11%
Constellation Brands Inc.
$119.82
-1.11%
Live Nation Entertainment, Inc.
$119.82
-1.11%
Shopify Inc.
$119.82
-1.11%
Sirius Xm Holdings Inc.
$119.82
-1.11%
Corning Inc.
$119.82
-1.11%
Cummins Inc.
$119.82
-1.11%
Ishares Core U.s. Value Etf
$119.82
-1.11%